Experiment: 2MIZ

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N TROSY-HSQC	20mM mM sodium phosphate, 5 % [U-99% 2H] D2O, 50 mM sodium chloride, 0.2-0.5 mM [U-13C; U-15N; U-2H] protein	95% H2O/5% D2O	0.110	6.5	ambient	285
2	3D HNCA	20mM mM sodium phosphate, 5 % [U-99% 2H] D2O, 50 mM sodium chloride, 0.2-0.5 mM [U-13C; U-15N; U-2H] protein	95% H2O/5% D2O	0.110	6.5	ambient	285
3	3D HNCACB	20mM mM sodium phosphate, 5 % [U-99% 2H] D2O, 50 mM sodium chloride, 0.2-0.5 mM [U-13C; U-15N; U-2H] protein	95% H2O/5% D2O	0.110	6.5	ambient	285
4	3D HNCO	20mM mM sodium phosphate, 5 % [U-99% 2H] D2O, 50 mM sodium chloride, 0.2-0.5 mM [U-13C; U-15N; U-2H] protein	95% H2O/5% D2O	0.110	6.5	ambient	285
5	3D HN(CA)CO	20mM mM sodium phosphate, 5 % [U-99% 2H] D2O, 50 mM sodium chloride, 0.2-0.5 mM [U-13C; U-15N; U-2H] protein	95% H2O/5% D2O	0.110	6.5	ambient	285
6	2D 1H-15N ARTSY	20mM mM sodium phosphate, 5 % [U-99% 2H] D2O, 200 mM sodium chloride, 0.2-0.5 mM [U-15N; U-2H] protein, 7.5 % Pf1 phage	95% H2O/5% D2O	0.260	6.5	ambient	285
7	2D 1H-15N ARTSY	20mM mM sodium phosphate, 5 % [U-99% 2H] D2O, 50 mM sodium chloride, 0.2-0.5 mM [U-15N; U-2H] protein, 5.5 % Ac/Bis-Ac, 20 % DADMAC	95% H2O/5% D2O	0.110	6.5	ambient	285
8	3D 1H-13C NOESY aliphatic (HCH)	20mM mM sodium phosphate, 5 % [U-99% 2H] D2O, 50 mM sodium chloride, 0.2-0.5 mM [ILVmethyl-13C; U-15N; U-2H; ILVmethyl-1H] protein	95% H2O/5% D2O	0.110	6.5	ambient	285
9	3D 1H-13C NOESY aliphatic (CCH)	20mM mM sodium phosphate, 5 % [U-99% 2H] D2O, 50 mM sodium chloride, 0.2-0.5 mM [ILVmethyl-13C; U-15N; U-2H; ILVmethyl-1H] protein	95% H2O/5% D2O	0.110	6.5	ambient	285
10	2D 1H-13C HMQC methyl	20mM mM sodium phosphate, 5 % [U-99% 2H] D2O, 50 mM sodium chloride, 0.2-0.5 mM [ILVmethyl-13C; U-15N; U-2H; ILVmethyl-1H] protein	95% H2O/5% D2O	0.110	6.5	ambient	285
11	3D 1H-15N NOESY (HCH)	20mM mM sodium phosphate, 5 % [U-99% 2H] D2O, 50 mM sodium chloride, 0.2-0.5 mM [ILVmethyl-13C; U-15N; U-2H; ILVmethyl-1H] protein	95% H2O/5% D2O	0.110	6.5	ambient	285
12	3D 1H-15N NOESY (HCN)	20mM mM sodium phosphate, 5 % [U-99% 2H] D2O, 50 mM sodium chloride, 0.2-0.5 mM [ILVmethyl-13C; U-15N; U-2H; ILVmethyl-1H] protein	95% H2O/5% D2O	0.110	6.5	ambient	285
13	3D 1H-15N NOESY (HNH)	20mM mM sodium phosphate, 5 % [U-99% 2H] D2O, 50 mM sodium chloride, 0.2-0.5 mM [U-15N; U-2H] protein	95% H2O/5% D2O	0.110	6.5	ambient	285
14	3D 1H-15N NOESY (NNH)	20mM mM sodium phosphate, 5 % [U-99% 2H] D2O, 50 mM sodium chloride, 0.2-0.5 mM [U-15N; U-2H] protein	95% H2O/5% D2O	0.110	6.5	ambient	285
15	SIM-HMCM(CGCBCA)CO	20mM mM sodium phosphate, 5 % [U-99% 2H] D2O, 50 mM sodium chloride, 0.2-0.5 mM [U-13C; U-15N; U-2H; ILVmethyl-1H] protein	95% H2O/5% D2O	0.110	6.5	ambient	285
16	HMCM(CG)CBCA	20mM mM sodium phosphate, 5 % [U-99% 2H] D2O, 50 mM sodium chloride, 0.2-0.5 mM [U-13C; U-15N; U-2H; ILVmethyl-1H] protein	95% H2O/5% D2O	0.110	6.5	ambient	285

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	Avance	900
2	Bruker	Avance	600
3	Bruker	Avance	800
4	Bruker	Avance	600

NMR Refinement
Method	Details	Software
RASREC	The high degree of order obtained for residues 21-22 and 175-176 in the deposited ensemble is inconsistent with the chemical shift-derived order parameters (<0.7) that suggest some residual mobility for these residues	nmrPipe

NMR Ensemble Information
Conformer Selection Criteria	target function
Conformers Calculated Total Number	10000
Conformers Submitted Total Number	10
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	data analysis	nmrPipe		Delaglio, Zhengrong and Bax
2	chemical shift assignment	sparky		Goddard
3	collection	TOPSPIN	3.1	Bruker Biospin
4	structure solution	CS-Rosetta	3.0	Shen, Vernon, Baker and Bax
5	refinement	CS-Rosetta

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.